H.I.G. Capital News
-
November 5, 2019 - H.I.G. BioHealth Provides Equity Financing for Clarify Medical
MIAMI – November 5, 2019 – H.I.G. BioHealth Partners (“H.I.G.”), the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global private equity investment firm with over $34 billion of equity capital under management,* co-led an $18M commercialization round…
-
November 4, 2019 - H.I.G. Capital Completes Acquisition of BioVectra
MIAMI – November 4, 2019 – H.I.G. Capital ("H.I.G."), a leading global private equity investment firm with over $34 billion of equity capital under management, is pleased to announce that one of its affiliates has completed the acquisition of BioVectra Inc. (“BioVectra” or the…
-
SAN DIEGO, CA & ALBUQUERQUE, NM – July 30, 2019 - Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis, prognosis, and monitoring while optimizing…
-
July 16, 2019 - Exagen Inc. Completes $22.6 Million Financing
SAN DIEGO, CA & ALBUQUERQUE, NM – July 16, 2019 - Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis, prognosis, and monitoring while optimizing…
-
AUSTIN, TX - June 24, 2019 - Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that the final patient has been enrolled in the Multi-Center ESG Randomized Interventional Trial…
-
June 18, 2019 - H.I.G. BioHealth Partners Completes Sale of Vertiflex to Boston Scientific
MIAMI – June 18, 2019 - H.I.G. BioHealth Partners (“H.I.G.”), the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global private equity investment firm with over $30 billion of equity capital under management,* recently announced the sale of Vertiflex, Inc.…
-
WAYNE, PA – June 18, 2019 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today welcomed the peer-reviewed publication, “Dissections After Infrainguinal Percutaneous Transluminal Angioplasty (PTA): Systematic Review…
-
June 18, 2019 - CardioFocus Launches 100th HeartLight® Center Worldwide
MARLBOROUGH, MA – June 18, 2019 – CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the HeartLight® Endoscopic Ablation System is now offered at more than 100 hospitals worldwide. The HeartLight…
-
SAN DIEGO – June 17, 2019 – Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that it has completed enrollment in the "STAR Study," a Phase 2 dose ranging study of tolperisone in acute muscle spasms…
-
MARLBOROUGH, MA – May 10, 2019 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3 System for the treatment…
-
JATENZO is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult men, and the first oral testosterone medicine approved in more than 60 years. 87 percent of hypogonadal men treated with JATENZO in the pivotal Phase 3 study…
-
March 26, 2019 - Apollo Endosurgery Appoints John Barr to Board of Directors
AUSTIN, TX - March 26, 2019 - The Board of Directors of Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that John Barr has been appointed to Apollo’s Board of Directors…
-
March 26, 2019 - On Target Laboratories Appoints Executive Vice President of Regulatory and Quality
WEST LAFAYETTE, IN - March 26, 2019 - On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today the appointment of Donna Haire as Executive Vice President of Regulatory and Quality.…
-
MARLBOROUGH, MA – March 25, 2019 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System. The HeartLight X3 System is a third…
-
MARLBOROUGH, MA – March 5, 2019 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the first enrollments in a clinical study evaluating use of the HeartLight X3 System in an early persistent AFib…